Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291459 | 0.93 | S1PR1 (0.37) | GRM7MAPTCRHR1PDE2ATP53 | |
| SCHEMBL6291398 | 0.92 | GRM7 (0.40) | GRM7MAPTCRHR1PDE2ALMNA | |
| SCHEMBL6291832 | 0.91 | GRM7 (0.41) | GRM7MAPTLMNATP53TDP2 | |
| SCHEMBL6288428 | 0.86 | MAPT (0.31) | MAPTTP53ALDH1A1 | |
| SCHEMBL6288552 | 0.85 | GRM7 (0.38) | GRM7MAPTCRHR1TP53 | |
| SCHEMBL6288587 | 0.84 | GRM7 (0.44) | GRM7MAPTLMNATP53TDP2 | |
| SCHEMBL6291757 | 0.79 | GRM7 (0.41) | GRM7MAPTLMNATDP2ALDH1A1 | |
| SCHEMBL6291357 | 0.79 | SMN1; SMN2 (0.39) | MAPTTP53ALDH1A1 | |
| SCHEMBL6288630 | 0.78 | S1PR1 (0.38) | GRM7MAPT | |
| SCHEMBL6291873 | 0.77 | MAPT (0.31) | MAPTLMNATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936609-B2 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | PDE3A, PDE2A, PDE4A | GRM7 2512/4885MAPT 1159/4885CRHR1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.